The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
List view / Grid view
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
The UK International Coronavirus Network (UK-ICN) aims to enhance knowledge of the virus family to prepare responses for future outbreaks.
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
Researchers have used CRISPR and cryogenic electron microscopy to unravel the workings of two receptors involved in diseases such as cancer and COVID-19.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
Researchers have established an organoid biobank to search for genes that are essential for the spreading of SARS-CoV-2 infection.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
Researchers have developed a novel algorithm, “scArches”, that can compare data on single-cell genomics to better understand diseases.